Featured Article

Where is RBQM Heading in The Future With AI?

Richard Young, Chief Strategy Officer at CluePoints, shares insights on AI and risk-based quality management (RBQM) in clinical trials. With experience at both CluePoints and Veeva, Young discusses AI’s role, transparency, and the future of risk management in clinical trials.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Download
Press Release
CluePoints Appoints Martin Magazzolo as Chief Commercial Officer
  • Wayne, PA – July 27, 2026 – CluePoints, provider of leading statistical and AI-driven software solutions,...
Read More
Press Release
CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM
  • New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing...
Read More
Blog
The Hidden Inspection Risk in Your Medical and Safety Review Workflow
  • You have just been told an inspection is coming. Your team’s first reaction is not to...
Read More